Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAMES SWINEHART

NPI
1073624748
CMS profile
1308298
Location
DENVER, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2020 · Entire year

$124.99

1 record · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2020 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $124.99 1

By paying entity

PY2020 · entire year · sorted by reported total

Paying entityAmountRecords
AbbVie Inc. $124.99 1

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAMES SWINEHART

NPI 1073624748 · CMS profile ID 1308298

DENVER, CO

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1073624748?year=2020&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAMES SWINEHART, NPI 1073624748, CMS profile ID 1308298. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1073624748?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
APA 7
IndustryPayments. (2026). JAMES SWINEHART, NPI 1073624748, CMS profile ID 1308298. General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1073624748?year=2020&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019.
Bluebook
JAMES SWINEHART, NPI 1073624748, CMS profile ID 1308298, IndustryPayments, General Payments, PY2020; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–1 of 1 matching records. This page contains 1 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/a08c4b30-5cf3-4948-ad40-36f404619019. https://industrypayments.org/provider/npi-1073624748?year=2020&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2020

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2020 · Physicians and non-physician practitioners · CMS publication 2026-06-30

1 matching record · $124.99 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 1 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–1 of 1.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
AbbVie Inc. $124.9901/14/2020 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 722149011 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $416.80 5
PY2020 $124.99 1
PY2021 $134.99 7
PY2022 $494.03 19
PY2023 $358.05 15
PY2024 $271.99 7
PY2025 $115.97 3

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $185,640.97 29
PY2024 Principal investigator $120,209.82 11
PY2023 Principal investigator $160,441.06 26
PY2022 Principal investigator $44,976.11 8
PY2021 Principal investigator $69,549.27 15
PY2020 Principal investigator $60,341.63 9
PY2019 Principal investigator $287,818.61 49

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

49 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 LEO Pharma AS $2,637.00 09/12/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
LONG TERM STUDY LEO 90100 ON THE BODY No dispute reported 06/30/2026 686858343
Principal investigator 1 Aclaris Therapeutics, Inc. $1,970.00 08/23/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER
RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 6 MONTHS IN ADULT SUBJECTS WITH STABLE PATCHY ALOPECIA AREATA No dispute reported 06/30/2026 700990091
Principal investigator 1 Aclaris Therapeutics, Inc. $180.00 08/23/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER
RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 6 MONTHS IN ADULT SUBJECTS WITH STABLE PATCHY ALOPECIA AREATA No dispute reported 06/30/2026 700990093
Principal investigator 1 Aclaris Therapeutics, Inc. $1,780.00 08/23/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER
AN OPEN-LABEL SAFETY, TOLERABILITY, AND EFFICACY STUDY IN MALE AND FEMALE SUBJECTS WITH ANDROGENETIC ALOPECIA TREATED WITH ATI-502 TOPICAL SOLUTION No dispute reported 06/30/2026 700990123
Principal investigator 1 Aclaris Therapeutics, Inc. $4,600.00 08/22/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700989995
Principal investigator 1 Aclaris Therapeutics, Inc. $785.00 08/20/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 28 DAYS IN ADULT SUBJECTS WITH ALOPECIA UNIVERSALIS AND ALOPECIA TOTALIS WITH A 6-MONTH LONG-TERM OPEN-LABEL EXTENSION No dispute reported 06/30/2026 700989809
Principal investigator 1 Aclaris Therapeutics, Inc. $1,500.00 08/20/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700989813
Principal investigator 1 Aclaris Therapeutics, Inc. $1,700.00 08/01/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700989675
Principal investigator 1 Aclaris Therapeutics, Inc. $4,935.00 07/30/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 28 DAYS IN ADULT SUBJECTS WITH ALOPECIA UNIVERSALIS AND ALOPECIA TOTALIS WITH A 6-MONTH LONG-TERM OPEN-LABEL EXTENSION No dispute reported 06/30/2026 700989529
Principal investigator 1 Aclaris Therapeutics, Inc. $9,600.00 07/30/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700989531
Principal investigator 1 Aclaris Therapeutics, Inc. $75.00 07/26/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER
AN OPEN-LABEL SAFETY, TOLERABILITY, AND EFFICACY STUDY IN MALE AND FEMALE SUBJECTS WITH ANDROGENETIC ALOPECIA TREATED WITH ATI-502 TOPICAL SOLUTION No dispute reported 06/30/2026 700989355
Principal investigator 1 Aclaris Therapeutics, Inc. $1,705.00 07/26/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER
AN OPEN-LABEL SAFETY, TOLERABILITY, AND EFFICACY STUDY IN MALE AND FEMALE SUBJECTS WITH ANDROGENETIC ALOPECIA TREATED WITH ATI-502 TOPICAL SOLUTION No dispute reported 06/30/2026 700989358
Principal investigator 1 Aclaris Therapeutics, Inc. $5,175.00 07/23/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS No dispute reported 06/30/2026 700989319
Principal investigator 1 Aclaris Therapeutics, Inc. $2,085.00 07/23/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 28 DAYS IN ADULT SUBJECTS WITH ALOPECIA UNIVERSALIS AND ALOPECIA TOTALIS WITH A 6-MONTH LONG-TERM OPEN-LABEL EXTENSION No dispute reported 06/30/2026 700989321
Principal investigator 1 Aclaris Therapeutics, Inc. $3,380.00 06/25/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER
AN OPEN-LABEL SAFETY, TOLERABILITY, AND EFFICACY STUDY IN MALE AND FEMALE SUBJECTS WITH ANDROGENETIC ALOPECIA TREATED WITH ATI-502 TOPICAL SOLUTION No dispute reported 06/30/2026 700989145
Principal investigator 1 Aclaris Therapeutics, Inc. $2,000.00 06/20/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700988847
Principal investigator 1 Aclaris Therapeutics, Inc. $3,900.00 06/20/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700988849
Principal investigator 1 Aclaris Therapeutics, Inc. $3,000.00 06/20/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700988853
Principal investigator 1 Aclaris Therapeutics, Inc. $1,530.00 05/30/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER
AN OPEN-LABEL SAFETY, TOLERABILITY, AND EFFICACY STUDY IN MALE AND FEMALE SUBJECTS WITH ANDROGENETIC ALOPECIA TREATED WITH ATI-502 TOPICAL SOLUTION No dispute reported 06/30/2026 700988729
Principal investigator 1 Aclaris Therapeutics, Inc. $2,700.00 05/30/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER
RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 6 MONTHS IN ADULT SUBJECTS WITH STABLE PATCHY ALOPECIA AREATA No dispute reported 06/30/2026 700988769
Principal investigator 1 Aclaris Therapeutics, Inc. $5,585.00 05/28/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS No dispute reported 06/30/2026 700988587
Principal investigator 1 Aclaris Therapeutics, Inc. $3,200.00 05/28/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700988590
Principal investigator 1 Aclaris Therapeutics, Inc. $6,050.00 05/23/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700988417
Principal investigator 1 Aclaris Therapeutics, Inc. $3,860.00 04/30/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER
AN OPEN-LABEL SAFETY, TOLERABILITY, AND EFFICACY STUDY IN MALE AND FEMALE SUBJECTS WITH ANDROGENETIC ALOPECIA TREATED WITH ATI-502 TOPICAL SOLUTION No dispute reported 06/30/2026 700988227
Principal investigator 1 Aclaris Therapeutics, Inc. $5,235.00 04/30/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER
RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 6 MONTHS IN ADULT SUBJECTS WITH STABLE PATCHY ALOPECIA AREATA No dispute reported 06/30/2026 700988240
Principal investigator 1 Aclaris Therapeutics, Inc. $11,100.00 04/25/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700988137
Principal investigator 1 Aclaris Therapeutics, Inc. $5,295.00 04/25/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS No dispute reported 06/30/2026 700988141
Principal investigator 1 Aclaris Therapeutics, Inc. $5,800.00 03/29/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER
RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 6 MONTHS IN ADULT SUBJECTS WITH STABLE PATCHY ALOPECIA AREATA No dispute reported 06/30/2026 700987827
Principal investigator 1 Aclaris Therapeutics, Inc. $3,410.00 03/27/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER
AN OPEN-LABEL SAFETY, TOLERABILITY, AND EFFICACY STUDY IN MALE AND FEMALE SUBJECTS WITH ANDROGENETIC ALOPECIA TREATED WITH ATI-502 TOPICAL SOLUTION No dispute reported 06/30/2026 700987749
Principal investigator 1 Aclaris Therapeutics, Inc. $11,070.00 03/19/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS No dispute reported 06/30/2026 700987535
Principal investigator 1 Aclaris Therapeutics, Inc. $19,550.00 03/19/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700987669
Principal investigator 1 Merck Sharp & Dohme Corporation $1,290.61 03/14/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER
A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety,Tolerability of Subcutaneous SCH 900222,MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis Protocol NO. MK-3222-011 No dispute reported 06/30/2026 691369413
Principal investigator 1 Aclaris Therapeutics, Inc. $2,000.00 03/07/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 28 DAYS IN ADULT SUBJECTS WITH ALOPECIA UNIVERSALIS AND ALOPECIA TOTALIS WITH A 6-MONTH LONG-TERM OPEN-LABEL EXTENSION No dispute reported 06/30/2026 700987463
Principal investigator 1 Aclaris Therapeutics, Inc. $5,895.00 03/05/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER
RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 6 MONTHS IN ADULT SUBJECTS WITH STABLE PATCHY ALOPECIA AREATA No dispute reported 06/30/2026 700987141
Principal investigator 1 Aclaris Therapeutics, Inc. $5,000.00 03/05/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 28 DAYS IN ADULT SUBJECTS WITH ALOPECIA UNIVERSALIS AND ALOPECIA TOTALIS WITH A 6-MONTH LONG-TERM OPEN-LABEL EXTENSION No dispute reported 06/30/2026 700987151
Principal investigator 1 Aclaris Therapeutics, Inc. $12,210.00 03/05/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS No dispute reported 06/30/2026 700987239
Principal investigator 1 Aclaris Therapeutics, Inc. $23,000.00 03/05/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700987383
Principal investigator 1 Aclaris Therapeutics, Inc. $5,000.00 02/26/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700987047
Principal investigator 1 Aclaris Therapeutics, Inc. $2,640.00 02/26/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER
AN OPEN-LABEL SAFETY, TOLERABILITY, AND EFFICACY STUDY IN MALE AND FEMALE SUBJECTS WITH ANDROGENETIC ALOPECIA TREATED WITH ATI-502 TOPICAL SOLUTION No dispute reported 06/30/2026 700987061
Principal investigator 1 Aclaris Therapeutics, Inc. $3,520.00 02/07/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER
AN OPEN-LABEL SAFETY, TOLERABILITY, AND EFFICACY STUDY IN MALE AND FEMALE SUBJECTS WITH ANDROGENETIC ALOPECIA TREATED WITH ATI-502 TOPICAL SOLUTION No dispute reported 06/30/2026 700986855
Principal investigator 1 Merck Sharp & Dohme Corporation $5,232.00 01/31/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER
A 52-Week, Phase 3, Randomized, Active Comparator and Placebo-Controlled, Parallel Design Study to Evaluate the Efficacy and Safety,Tolerability of Subcutaneous SCH 900222,MK-3222, Followed by an Optional Long-Term Safety Extension Study, in Subjects With Moderate-to-Severe Chronic Plaque Psoriasis Protocol NO. MK-3222-011 No dispute reported 06/30/2026 691344803
Principal investigator 1 Aclaris Therapeutics, Inc. $14,465.00 01/22/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS No dispute reported 06/30/2026 700986529
Principal investigator 1 Aclaris Therapeutics, Inc. $34,175.00 01/22/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700986581
Principal investigator 1 Aclaris Therapeutics, Inc. $4,029.00 01/10/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS No dispute reported 06/30/2026 700986469
Principal investigator 1 Aclaris Therapeutics, Inc. $1,765.00 01/03/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER
AN OPEN-LABEL SAFETY, TOLERABILITY, AND EFFICACY STUDY IN MALE AND FEMALE SUBJECTS WITH ANDROGENETIC ALOPECIA TREATED WITH ATI-502 TOPICAL SOLUTION No dispute reported 06/30/2026 700986213
Principal investigator 1 Aclaris Therapeutics, Inc. $2,065.00 01/03/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER
AN OPEN-LABEL SAFETY, TOLERABILITY, AND EFFICACY STUDY IN MALE AND FEMALE SUBJECTS WITH ANDROGENETIC ALOPECIA TREATED WITH ATI-502 TOPICAL SOLUTION No dispute reported 06/30/2026 700986219
Principal investigator 1 Aclaris Therapeutics, Inc. $8,450.00 01/03/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A PHASE 3 RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED, PARALLEL GROUP STUDY OF A-101 TOPICAL SOLUTION APPLIED TWICE A WEEK IN SUBJECTS WITH COMMON WARTS No dispute reported 06/30/2026 700986249
Principal investigator 1 Aclaris Therapeutics, Inc. $18,015.00 01/03/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER INC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-501 ORAL SUSPENSION COMPARED TO PLACEBO IN ADULT SUBJECTS WITH ALOPECIA AREATA, ALOPECIA UNIVERSALIS OR ALOPECIA TOTALIS No dispute reported 06/30/2026 700986383
Principal investigator 1 Aclaris Therapeutics, Inc. $3,675.00 01/02/2019 Non-covered Recipient Entity
COLORADO MEDICAL RESEARCH CENTER
RANDOMIZED, DOUBLE-BLIND, VEHICLE-CONTROLLED MULTICENTER STUDY TO EVALUATE THE SAFETY, TOLERABILITY AND EFFICACY OF ATI-502 TOPICAL SOLUTION ADMINISTERED TWICE-DAILY FOR 6 MONTHS IN ADULT SUBJECTS WITH STABLE PATCHY ALOPECIA AREATA No dispute reported 06/30/2026 700986111